Loading company…
Refoxy Pharmaceuticals develops FOXO3-targeting therapeutics for pulmonary fibrosis and other age-related conditions.
Founded in 2020 in Cologne by Dr. Victor Bustos and Prof. Wolfgang Link, Refoxy Pharmaceuticals develops therapeutics targeting the FOXO3 transcription factor. Its small molecule activators are being developed for idiopathic pulmonary fibrosis and other fibrotic and cardiovascular conditions, using its F.act finder screening platform. The company targets healthcare systems in North America and Europe and generates income through pharmaceutical partnerships and licensing. In December 2024, it raised EUR 9.1 million in seed funding led by Boehringer Ingelheim, with participation from Apollo Health Ventures, NRW.Venture, and High-Tech Grunderfonds.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in